Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Por:
Bennett JC, Hetrich MK, Garcia-Quesada M, Sinkevitch JN, Knoll MD, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, Miguel S, Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad'arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Munoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Khan AS, Savrasova L, Scott JA, Skoczynska A, Suga S, Linden MV, Verani JR, Gottberg AV, Winje BA, Yildirim I, Zerouali K, Hayford K and The Pserenade Team
Publicada:
1 abr 2021
Ahead of Print:
27 mar 2021
Resumen:
Streptococcus pneumoniae serotype 1 (ST1) was an important cause of invasive pneumococcal disease (IPD) globally before the introduction of pneumococcal conjugate vaccines (PCVs) containing ST1 antigen. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project gathered ST1 IPD surveillance data from sites globally and aimed to estimate PCV10/13 impact on ST1 IPD incidence. We estimated ST1 IPD incidence rate ratios (IRRs) comparing the pre-PCV10/13 period to each post-PCV10/13 year by site using a Bayesian multi-level, mixed-effects Poisson regression and all-site IRRs using a linear mixed-effects regression (N = 45 sites). Following PCV10/13 introduction, the incidence rate (IR) of ST1 IPD declined among all ages. After six years of PCV10/13 use, the all-site IRR was 0.05 (95% credibility interval 0.04-0.06) for all ages, 0.05 (0.04-0.05) for <5 years of age, 0.08 (0.06-0.09) for 5-17 years, 0.06 (0.05-0.08) for 18-49 years, 0.06 (0.05-0.07) for 50-64 years, and 0.05 (0.04-0.06) for >= 65 years. PCV10/13 use in infant immunization programs was followed by a 95% reduction in ST1 IPD in all ages after approximately 6 years. Limited data availability from the highest ST1 disease burden countries using a 3 + 0 schedule constrains generalizability and data from these settings are needed.
Filiaciones:
Bennett JC:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Hetrich MK:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Garcia-Quesada M:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Sinkevitch JN:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Knoll MD:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Feikin DR:
Independent Consultant, 1296 Coppet, Switzerland
Zeger SL:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Kagucia EW:
KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
Cohen AL:
World Health Organization, 1202 Geneva, Switzerland
Ampofo K:
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
Brandileone MC:
National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil
Bruden D:
Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK 99508, USA
Camilli R:
Department of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy
Castilla J:
CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
Instituto de Salud Pública de Navarra-IdiSNA, 31003 Pamplona, Navarra, Spain
Chan G:
Singapore Ministry of Health, Communicable Diseases Division, Singapore 308442, Singapore
Cook H:
Centre for Disease Control, Department of Health and Community Services, Darwin, NT 8000, Australia
Cornick JE:
Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool CH64 7TE, UK
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre 3, Malawi
Dagan R:
Faculty of Health Sciences, Ben-Gurion University of the Negev, 8410501 Beer-Sheva, Israel
Dalby T:
Bacteria, Parasites and Fungi, Statens Serum Institut, DK-2300 Copenhagen, Denmark
Danis K:
Santé Publique France, the French National Public Health Agency, Saint Maurice CEDEX, 94415 Paris, France
Miguel S:
Epidemiology Department, Dirección General de Salud Pública, 28009 Madrid, Spain
Wals P:
Department of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada
Desmet S:
Department of Microbiology, Immunology and Transplantation, KU Leuven, BE-3000 Leuven, Belgium
National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, 3000 Leuven, Belgium
Georgakopoulou T:
National Public Health Organisation, 15123 Athens, Greece
Gilkison C:
Epidemiology Team, Institute of Environmental Science and Research, Porirua, 5240 Wellington, New Zealand
Grgic-Vitek M:
Communicable Diseases Centre, National Institute of Public Health, 1000 Ljubljana, Slovenia
Hammitt LL:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
Hilty M:
Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland
Ho PL:
Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong, China
Jayasinghe S:
National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia
Kellner JD:
Department of Pediatrics, University of Calgary, and Alberta Health Services, Calgary, AB T3B 6A8, Canada
Kleynhans J:
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 2192 Johannesburg, South Africa
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, 2000 Johannesburg, South Africa
Knol MJ:
National Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands
Kozakova J:
National Institute of Public Health (NIPH), 100 42, Praha Czech Republic
Kristinsson KG:
Department of Clinical Microbiology, Landspitali-The National University Hospital, Hringbraut, 101 Reykjavik, Iceland
Ladhani SN:
Immunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK
MacDonald L:
Public Health Scotland, Glasgow G2 6QE, UK
Mackenzie GA:
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London, WC1E 7HT, UK
Medical Research Council Unit the Gambia atLondon School of Hygiene & Tropical Medicine, P.O. Box 273, Banjul, The Gambia
New Vaccines Group, Murdoch Children's Research Institute, Parkville, Melbourne, 3052, Victoria, Australia
Mad'arová L:
National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, 975 56 Banská Bystrica, Slovakia
McGeer A:
Toronto Invasive Bacterial Diseases Network, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
Mereckiene J:
HSE Health Protection Surveillance Centre, Mountjoy, Dublin D01 A4A3, Ireland
Morfeldt E:
Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden
Mungun T:
National Center of Communicable Diseases (NCCD), Ministry of Health, Bayanzurkh District, Ulaanbaatar 13336, Mongolia
Munoz-Almagro C:
CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain
Medicine Department, Universitat Internacional de Catalunya, 08017 Barcelona, Spain
Molecular Microbiology Department, Hospital Sant Joan de Déu Research Institute, 08950 Esplugues de Llobregat, Barcelona, Spain
Nuorti JP:
Department of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland
Health Sciences Unit, Faculty of Social Sciences, University of Tampere, 33100 Tampere, Finland
Paragi M:
Centre for Medical Microbiology, National Laboratory of Health, Environment and Food, 2000 Maribor, Slovenia
Pilishvili T:
National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Puentes R:
Instituto de Salud Pública de Chile, 7780050 Santiago, Santiago Metropolitan, Chile
Saha SK:
Child Health Research Foundation, Dhaka 1207, Bangladesh
Khan AS:
Ministry of Health and Medical Services, Suva, Fiji
Savrasova L:
Centre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia
Doctoral Studies Department, Riga Stradinš University, 1007 Riga, Latvia
Scott JA:
KEMRI-Wellcome Trust Research Programme, Epidemiology and Demography Department, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya
Skoczynska A:
National Reference Centre for Bacterial Meningitis, National Medicines Institute, 00-725 Warsaw, Poland
Suga S:
Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Tsu, Mie 514-0125, Japan
Linden MV:
National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany
Verani JR:
National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Centers for Disease Control and Prevention (CDC), Center for Global Health (CGH), Division of Global Health Protection (DGHP), Nairobi, Kenya
Gottberg AV:
Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 2192 Johannesburg, South Africa
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Braamfontein, Johannesburg 2000, South Africa
Winje BA:
Department of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway
Yildirim I:
Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT 06504, USA
Zerouali K:
Bacteriology-Virology and Hospital Hygiene Laboratory, Ibn Rochd University Hospital Centre, Casablanca 20250, Morocco
Department of Microbiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca 20000, Morocco
Hayford K:
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Green Submitted, Green Accepted, gold
|